Alto Neuroscience (ANRO) Consolidated Net Income (2023 - 2026)

Alto Neuroscience has reported Consolidated Net Income for 4 years, with the latest figure at -$26.1 million in Q1 2026.

• Quarterly Consolidated Net Income fell 64.82% year-over-year to -$26.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 3479.2% YoY) and the FY2025 annual result came in at -$111.9 million, down 15.18% from the prior year.
• Consolidated Net Income slipped to -$26.1 million in Q1 2026 per ANRO's latest filing, from -$15.3 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$7.3 million in Q1 2023 and troughed at -$1.9 billion in Q3 2025.
• A 4-year average of -$183.6 million and a median of -$15.3 million in 2025 frame the typical range for Consolidated Net Income.
• The widest YoY moves for Consolidated Net Income: up 2.64% in 2025, down 10975.11% in 2025.
• Over 4 years, Consolidated Net Income stood at -$10.9 million in 2023, then plunged by 36.03% to -$14.9 million in 2024, then retreated by 2.64% to -$15.3 million in 2025, then tumbled by 71.25% to -$26.1 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$26.1 million, -$15.3 million, and -$1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.